Allergy treatment resumes US clinical development after 8 year break
This article was originally published in Scrip
Executive Summary
Allergy Therapeutics is ready to re-start clinical trials in the US with its Pollinex Quattro Grass allergy treatment, eight years after it was placed on clinical hold by the FDA, and three years after that hold was lifted.